ERNA
Ernexa Therapeutics Inc.
There isn't enough reported data to score ERNA yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
ERNA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
ERNA's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ERNA PE Valuation
ERNA has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
ERNA Forward outlook
There aren't enough analyst estimates for ERNA to show an outlook.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
ERNA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2022 | -$4,308.75 | +$13,541.25 |
| Q2 2022 | -$16,125.00 | -$3,525.00 |
| Q1 2022 | -$17,475.00 | +$3,675.00 |
| Q4 2021 | -$21,000.00 | +$1,650.00 |
| Q3 2021 | -$17,850.00 | +$13,200.00 |
| Q2 2021 | -$12,600.00 | +$12,750.00 |
| Q1 2021 | -$21,150.00 | -$5,700.00 |
| Q4 2020 | -$22,650.00 | -$11,850.00 |
OSCR has the stronger earnings trend. Trailing diluted EPS is down 172% for ERNA versus OSCR up 147%.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
ERNA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2024 | $1K | -94% |
| Q3 2024 | $487K | +855% |
| Q4 2020 | $1.2M | -77% |
ERNA's revenue has slid since its 2019 peak: $1,000 last quarter, down 94% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2024 | -269700% | -235788 points |
| Q3 2024 | -464% | +10330 points |
| Q2 2024 | -10491% | N/A |
| Q1 2024 | -12313% | N/A |
| Q4 2023 | -33912% | N/A |
| Q3 2023 | -10794% | N/A |
| Q4 2020 | -63% | -39 points |
| Q3 2020 | -96% | N/A |
ERNA's operating margin was −269700% last quarter, down 235788 points from the same quarter a year ago, near the bottom of its range since 2019.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over ERNA in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
ERNA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$1.2M | +$2.4M |
| Q4 2024 | -$3.5M | +$1.1M |
| Q3 2024 | -$6.3M | -$478K |
| Q2 2024 | -$2.5M | +$1.4M |
| Q1 2024 | -$3.8M | +$2.2M |
| Q4 2023 | -$4.7M | +$776K |
| Q3 2023 | -$5.8M | +$333K |
| Q2 2023 | -$3.9M | +$308K |
OSCR has the stronger cash trend. Its trailing FCF is up 545% versus its history, compared with ERNA at up 35%.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
ERNA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | 0% | -- |
| 3 years | +7298% | +14.2K shares |
ERNA has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ERNA Net Leverage
ERNA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
ERNA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.0 | Oversold |
| Stochastic | 2.9 | Oversold |
ERNA's weekly RSI is 30 (oversold) and its Stochastic is 3 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ERNA PE vs Healthcare Sector
ERNA has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
ERNA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.33 | 23% below |
| 20 week MA | $3.74 | 52% below |
| 50 week MA | $10.2 | 82% below |
| 100 week MA | $40.6 | 96% below |
| 200 week MA | $416.1 | 100% below |
ERNA is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over ERNA on trend strength, trading above more of its moving averages.
ERNA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $33,600.0 | $32,250.0 | -4% |
| 2021 | $32,250.0 | $37,425.0 | +16% |
| 2022 | $37,425.0 | $1,286.3 | -97% |
| 2023 | $1,286.3 | $675.0 | -48% |
| 2024 | $675.0 | $95.0 | -86% |
| 2025 | $95.0 | $30.3 | -68% |
| 2026 YTD | $30.3 | $1.79 | -94% |
ERNA has finished four years in a row lower, and it's down 94% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ERNA on returns for 2026, with the stronger performance.